BDTX · Black Diamond Therapeutics, Inc. · Executive Compensation
$1.32
-0.07 (-4.69%)
At close · Nov 20
Return incl. dividend (before tax)
Market Cap
$75.28M
Shares
57.47M
Volume · Nov 20
662.46K
Avg daily vol (3M)
697.63K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Mark A. Velleca | M.D., Ph.D. President and Chief Executive Officer | $2,234,919 |
| Sergey Yurasov | M.D., Ph.D. Chief Medical Officer | $1,352,097 |
| Brent Hatzis-Schoch | Chief Operating Officer and General Counsel | $1,282,245 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Mark A. Velleca | M.D., Ph.D. President and Chief Executive Officer | $2,855,111 |
| Sergey Yurasov | M.D., Ph.D. Chief Medical Officer | $1,514,820 |
| Brent Hatzis-Schoch | Esq.(6) Chief Operating Officer and General Counsel | $1,405,116 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Mark A. Velleca | M.D., Ph.D. President and Chief Executive Officer | $2,949,854 |
| David M. Epstein | Ph.D. Former President and Chief Executive Officer | $2,019,206 |
| Fang Ni | Pharm.D. Chief Business Officer and Interim Chief Financial Officer | $1,489,526 |
| Sergey Yurasov | M.D., Ph.D. Chief Medical Officer | $1,233,684 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| David M. Epstein | Ph.D. Former President and Chief Executive Officer | $1,644,857 |
| Brent Hatzis-Schoch | Chief Operating Officer, General Counsel | $911,227 |
| Fang Ni | Pharm.D. Chief Business Officer and Interim Chief Financial Officer | $909,759 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| David M. Epstein | President and Chief Executive Officer | $5,090,225 |
| Brent Hatzis-Schoch | Chief Operating Officer, General Counsel | $2,022,309 |
| Fang Ni | Pharm.D. Chief Business Officer and Chief Financial Officer | $1,674,570 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| David M. Epstein | President and Chief Executive Officer | $3,868,216 |
| Rachel Humphrey | Chief Medical Officer | $2,979,288 |
| Brent Hatzis-Schoch | Chief Operating Officer, General Counsel | $1,527,044 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| David M. Epstein | President and Chief Executive Officer | $3,346,081 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Erika Jones | principal financial officer | Appointed | 2024-10-07 |
| Fang Ni | Chief Business Officer, Chief Financial Officer and principal financial officer | Terminated | 2024-10-07 |
| Shannon Campbell | Class III director | Appointed | 2024-04-11 |
| Prakash Raman, Ph.D. | Class I director | Appointed | 2024-04-11 |
|
Wendy L. Dixon, Ph.D.
“Dr. Dixon’s decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.”
|
Board and all committees thereof, including her position as Chair of the Nominating and Corporate Governance Committee of the Bo | Resigned | 2024-04-11 |
|
Alexander Mayweg, Ph.D.
“Dr. Mayweg’s decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.”
|
Board of Directors | Resigned | 2024-04-11 |
|
Rajeev Shah
“Mr. Shah’s decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.”
|
member of the Company's Board of Directors | Resigned | 2024-01-18 |
| Mark Velleca, M.D., Ph.D. | Chief Executive Officer (CEO) | Appointed | 2023-09-18 |
| Mark A. Velleca | President and Chief Executive Officer and principal executive officer | Appointed | 2023-09-18 |
| David M. Epstein | President and Chief Executive Officer and principal executive officer | Terminated | 2023-09-18 |
| Mark A. Velleca, M.D., Ph.D. | Chairman of the Board | Appointed | 2022-12-19 |
|
Robert A. Ingram
“Mr. Ingram’s decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.”
|
Chairman of the Board | Resigned | 2022-12-19 |
| Wendy L. Dixon | Class III director | Appointed | 2022-04-07 |
|
Brad Bolzon
“Dr. Bolzon’s decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.”
|
Board of Directors | Resigned | 2022-04-07 |
| Erika Jones | principal accounting officer | Appointed | 2021-11-22 |
| Fang Ni, Pharm. D. | Interim Chief Financial Officer | Appointed | 2021-11-22 |
|
Thomas Leggett
“Mr. Leggett’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or procedures.”
|
Chief Financial Officer | Resigned | 2021-11-22 |
| Mark Velleca | Class I director | Appointed | 2021-08-10 |
| Christopher Roberts | Chief Scientific Officer | Resigned | 2021-08-05 |
| Elizabeth Buck | Chief Scientific Officer | Appointed | 2021-08-05 |
| Karsten Witt | Interim Chief Medical Officer | Appointed | 2021-08-05 |
Leadership
- Mark A. Velleca CEO
- Mark A. Velleca, M.D., Ph.D. CEO, Chairman
- Mark Velleca CEO, Board Member
- Mark Velleca, M.D., Ph.D. CEO, Board Member
- Erika Jones CFO, Chief Accounting Officer
- Fang Ni, Pharm. D. CFO
- Brent Hatzis-Schoch COO
- Elizabeth Buck CTO
- Kapil Dhingra Board Member
- Prakash Raman, Ph.D. Board Member
- Robert A. Ingram Board Member
- Shannon Campbell Board Member
Key facts
CIK
1701541
CUSIP
09203E105
13F (30d)
118 filings
105 filers
Visit website
Investor relations